Poolbeg Pharma on a a new cancer immunity

episode

Breakfast Business with Joe Lynam not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

More from Breakfast Business with Joe Lynam

K-shaped economy 6 min · 23 Dec 2025

Medtech firm secures funding to support its push for US regulatory clearance 8 min · 23 Dec 2025

Tuesday's business headlines 3 min · 23 Dec 2025

Volatile Geopolitics the New Norm 7 min · 22 Dec 2025

Monday's business headlines 9 min · 22 Dec 2025

A positive picture for the domestic economy 7 min · 19 Dec 2025

All episodes from Breakfast Business with Joe Lynam →

Report any issue

Source

Recorded30 Jul 2025

Publisherrss.podplaystudio.com

Handlerec:9174074

Show notes

Poolbeg Pharma, named after the infamous Red & white towers has been working on some very exciting new ideas including a new cancer immunity drug and a potential weight loss tablet. But most early drug developments fail to make it to the final round of testing on humans because it’s so risky and so expensive. And what does a pharma company like Poolbeg make of the EU-US trade deal with its 15% tariffs thus far? Jeremy Skillington, is the chief executive of Poolbeg pharma and joined Joe Lynam on the show this morning.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in